Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

HCW Biologics shares skyrocketed as the company entered a licensing agreement with China's WY Biotech for an immunotherapeutic product candidate.

The deal is focused on a preclinical molecule that could potentially be used to treat age-related illnesses, such as cancer.

Aclaris Therapeutics (NASDAQ:ACRS) shares gained 13% Monday morning after it announced a license deal to add potential best-in-class biologics assets to its pipeline. The biopharmaceutical company ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- ...